Where will dermatology land after USP publishes its updated Chapter 797 standards for sterile compounding?
As more drugs and treatment indications receive FDA clearance, how do the new arrivals compare to industry heavyweights?
Now that electronic health records are a staple in nearly all dermatologists' offices, what is involved in maintaining them?